JP2007509965A - Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法 - Google Patents

Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法 Download PDF

Info

Publication number
JP2007509965A
JP2007509965A JP2006538281A JP2006538281A JP2007509965A JP 2007509965 A JP2007509965 A JP 2007509965A JP 2006538281 A JP2006538281 A JP 2006538281A JP 2006538281 A JP2006538281 A JP 2006538281A JP 2007509965 A JP2007509965 A JP 2007509965A
Authority
JP
Japan
Prior art keywords
amount
agonist
activated receptor
peroxisome proliferator
niacin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509965A5 (enExample
Inventor
タワコル，レイフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2007509965A publication Critical patent/JP2007509965A/ja
Publication of JP2007509965A5 publication Critical patent/JP2007509965A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006538281A 2003-10-29 2004-10-29 Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法 Pending JP2007509965A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51589103P 2003-10-29 2003-10-29
PCT/US2004/035910 WO2005041878A2 (en) 2003-10-29 2004-10-29 Compositions and methods for increasing hdl and hdl-2b levels

Publications (2)

Publication Number Publication Date
JP2007509965A true JP2007509965A (ja) 2007-04-19
JP2007509965A5 JP2007509965A5 (enExample) 2007-12-13

Family

ID=34549456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538281A Pending JP2007509965A (ja) 2003-10-29 2004-10-29 Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法

Country Status (6)

Country Link
US (1) US20050148556A1 (enExample)
EP (1) EP1684704A2 (enExample)
JP (1) JP2007509965A (enExample)
CA (1) CA2543170A1 (enExample)
TW (1) TW200624125A (enExample)
WO (1) WO2005041878A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521915A (ja) * 2008-05-20 2011-07-28 セレニス セラピューティクス エス．エー． ナイアシン及びｎｓａｉｄ併用療法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US20080058292A1 (en) * 2003-10-29 2008-03-06 Raif Tawakol Method for increasing HDL and HDL-2b levels
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
WO2008091338A1 (en) * 2007-01-23 2008-07-31 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
WO2008100249A1 (en) * 2007-02-13 2008-08-21 Kos Life Sciences, Inc. Low flush niacin formulation
US20170042821A1 (en) * 2007-07-01 2017-02-16 Vitalis Llc Combination tablet with chewable outer layer
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2009033072A1 (en) * 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
RU2010153904A (ru) * 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Ниацин-содержащие композиции с модифицированным высвобождением
WO2009149058A2 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
EP2770978B1 (en) 2011-10-28 2018-01-10 Vitalis LLC Anti-flush compositions
WO2014159684A1 (en) * 2013-03-13 2014-10-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating or preventing insulin resistance or abnormal levels of circulating lipids in a mammal
US10695309B2 (en) * 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032942A1 (en) * 1995-04-19 1996-10-24 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
WO1999006052A1 (en) * 1997-07-31 1999-02-11 Kos Pharmaceuticals, Inc. Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
WO1999006046A1 (en) * 1997-07-31 1999-02-11 Kos Pharmaceuticals, Inc. Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
JP2001511444A (ja) * 1997-07-31 2001-08-14 コス ファーマスーティカルズ、インコーポレイテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤とニコチン酸化合物との組み合わせ、及び夜に１日１回高脂質血症を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3312593A (en) * 1965-03-10 1967-04-04 Carter Prod Inc Anti-inflammatory compositions of aspirin and niacin
US4080472A (en) * 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
AU2001288294A1 (en) * 2000-08-21 2002-03-04 Merck And Co., Inc. Anti-hypercholesterolemic drug combination
PE20020453A1 (es) * 2000-09-27 2002-06-06 Merck & Co Inc Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
WO2002040448A1 (en) * 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Pyridone derivatives as ap2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032942A1 (en) * 1995-04-19 1996-10-24 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
WO1999006052A1 (en) * 1997-07-31 1999-02-11 Kos Pharmaceuticals, Inc. Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
WO1999006046A1 (en) * 1997-07-31 1999-02-11 Kos Pharmaceuticals, Inc. Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
JP2001511444A (ja) * 1997-07-31 2001-08-14 コス ファーマスーティカルズ、インコーポレイテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤とニコチン酸化合物との組み合わせ、及び夜に１日１回高脂質血症を治療する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6008030848, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ ｆａｍｉｌｙ ｐｒａｃｔｉｃｅ, 1992, Ｖｏｌ．３４， Ｎｏ．２, ｐ．１６５−８ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521915A (ja) * 2008-05-20 2011-07-28 セレニス セラピューティクス エス．エー． ナイアシン及びｎｓａｉｄ併用療法

Also Published As

Publication number Publication date
CA2543170A1 (en) 2005-05-12
US20050148556A1 (en) 2005-07-07
EP1684704A2 (en) 2006-08-02
WO2005041878A2 (en) 2005-05-12
WO2005041878A3 (en) 2005-09-01
TW200624125A (en) 2006-07-16

Similar Documents

Publication Publication Date Title
RU2498795C2 (ru) Способы лечения неалкогольного стеатогепатита (nash) с применением цистеаминовых продуктов
JP4976281B2 (ja) 代謝を調節するための材料および方法
JP2007509965A (ja) Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法
AU2009222515A1 (en) Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
KR100540618B1 (ko) 의약 조성물
US20140221286A1 (en) Sodium channel blockers reduce glucagon secretion
EP0957923A1 (en) Sulfonylurea-glitazone synergistic combinations for diabetes
PT1853266E (pt) 2s,4r-cetoconazole para o tratamento de diabetes, síndrome metabólica e outras condições
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
US20120277269A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2020102337A1 (en) Combination treatment of nafld and nash
US20110190277A1 (en) Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
CN1210465A (zh) 治疗方法和药物组合物
US20080058292A1 (en) Method for increasing HDL and HDL-2b levels
US20070287685A1 (en) Medicinal composition containing FBPase inhibitor
JP4901218B2 (ja) 併用医薬
EA032705B1 (ru) Способ лечения или предупреждения энтеропатии
WO2009033078A2 (en) Compositions and methods for controlling cholesterol levels
JP7569492B2 (ja) 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
EP1905450A1 (en) Pharmaceutical composition containing ppar gamma agonist
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
JP2002220345A (ja) 脂肪肝改善剤
WO2014034871A1 (ja) 脂質異常症の予防又は治療薬
JPH09227371A (ja) 粥状動脈硬化抑制剤
JPWO2005107746A1 (ja) 脂質代謝異常の予防または治療用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110628